Benzinga · Aug 27, 2026
Beyond Air Has Been Granted Australian Patent Number 2020228618 Titled "System and method for delivery of gas to a tissue (for treatment of tumors)"
https://ipsearch.ipaustralia.gov.au/patents/2020393170
NASDAQ · XAIR
Beyond Air, Inc.
Healthcare · Medical - Devices
$3.66
Down-$0.31 (-7.81%)
Updated Sep 2, 2026, 7:31 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.6M
- P/E ratio
- -0.13
- Dividend yield
- 0.00%
- 52-week range
- $0.33 – $9.28
- Volume
- 265.99K
- Avg. volume
- 537.56K
Price performance
XAIR price history
1M range · 21 trading sessions · Daily adjusted prices
XAIR closed at $3.66 after 21 trading sessions, down 40.78% for the selected period.
- Last close
- $3.66
- Period change
- -40.78%
- Period low
- $3.66
- Period high
- $6.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 1, 2026 | $3.78 | $3.94 | $3.60 | $3.66 | 265.99K |
| Aug 31, 2026 | $4.52 | $4.52 | $3.85 | $3.97 | 8.75M |
| Aug 28, 2026 | $4.39 | $4.73 | $4.25 | $4.48 | 313.82K |
| Aug 27, 2026 | $4.94 | $5.70 | $4.6005 | $5.70 | 1.12M |
| Aug 26, 2026 | $4.96 | $4.97 | $4.7001 | $4.97 | 14.64K |
| Aug 25, 2026 | $4.68 | $5.0667 | $4.3748 | $4.98 | 289.66K |
| Aug 24, 2026 | $5.12 | $5.4899 | $4.85 | $4.91 | 22.01K |
| Aug 21, 2026 | $5.30 | $5.31 | $4.88 | $5.04 | 23.91K |
| Aug 20, 2026 | $5.12 | $5.5521 | $5.01 | $5.16 | 30.85K |
| Aug 19, 2026 | $5.95 | $5.95 | $5.09 | $5.21 | 72.76K |
| Aug 18, 2026 | $5.70 | $5.85 | $5.60 | $5.73 | 17.94K |
| Aug 17, 2026 | $6.25 | $6.25 | $5.71 | $5.71 | 22.18K |
| Aug 14, 2026 | $6.98 | $7.00 | $6.22 | $6.315 | 15.35K |
| Aug 13, 2026 | $6.65 | $7.23 | $5.89 | $6.92 | 58.72K |
| Aug 12, 2026 | $6.02 | $6.47 | $5.52 | $6.05 | 43.05K |
| Aug 11, 2026 | $5.32 | $6.22 | $5.17 | $5.84 | 45.27K |
| Aug 10, 2026 | $5.39 | $5.50 | $5.10 | $5.20 | 24.71K |
| Aug 7, 2026 | $5.54 | $5.87 | $5.36 | $5.36 | 12.77K |
| Aug 6, 2026 | $5.90 | $5.99 | $5.50 | $5.56 | 21.6K |
| Aug 5, 2026 | $6.37 | $6.37 | $5.48 | $5.69 | 38.66K |
| Aug 4, 2026 | $6.27 | $6.95 | $6.10 | $6.18 | 62.2K |
Latest XAIR news
The latest Smart Investors Daily articles mentioning XAIR.
Stock researchCompany · Overview
XAIR research
Overview
Company profile and research snapshot.
Company profile
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $1.00
- Implied upside
- —
- Analysts
- 11
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 27, 2026 | D. Boral Capital | Buy | — |
| Mar 18, 2026 | D. Boral Capital | Buy | — |
| Mar 10, 2026 | D. Boral Capital | Buy | — |
| Jan 21, 2026 | D. Boral Capital | Buy | — |
| Nov 11, 2025 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 25, 2026
Beyond Air Signs Agreement With UNIVO For NeuroNOS Stake Sale; Receives 19.99% UNIVO Equity And $0.01 Warrants
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closingBeyond Air eligible to receive up to $32.5 million in development and commercial milestone paymentsGARDEN
SeekingAlpha · Aug 13, 2026
Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call August 13, 2026 8:00 AM EDTCompany ParticipantsRobert Goodman - CEO & DirectorDaniel Moorhead - Chief...
Benzinga · Aug 13, 2026
Beyond Air Q1 EPS $(11.00) Misses $(9.40) Estimate, Sales $1.768M Miss $1.929M Estimate
Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(11.00) per share which missed the analyst consensus estimate of $(9.40) by 17.02 percent. This is a 64.13 percent increase over losses of $(30.67) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
